文献速递哮喘

呼出气一氧化氮在重症哮喘管理中的临床价值

Clinical utility of fractional exhaled nitric oxide in severe asthma management.
PubMed 文献 · Eur Respir J · 2020-03-26

本文综述呼出气一氧化氮(FeNO)在重症哮喘管理中的临床应用。FeNO主要用于预测吸入性糖皮质激素(ICS)反应、监测依从性及未使用ICS患者的诊断,并被证实可预测哮喘急性发作和肺功能下降,近期证据提示其可作为重症哮喘评估和管理及预测生物治疗反应的替代生物标志物。

要点

  • FeNO可预测ICS治疗反应、监测依从性,并用于未使用ICS患者的诊断。
  • FeNO水平升高与哮喘急性发作增多及肺功能下降相关。
  • FeNO可能作为重症哮喘评估管理及预测生物治疗反应的替代标志物。

核心结论

  • FeNO是哮喘管理中有用的生物标志物,在重症哮喘评估和生物治疗反应预测方面具有潜在价值。

主要发现

  • FeNO主要用于预测ICS反应、监测依从性及未使用ICS患者的诊断。
  • FeNO水平越高与哮喘急性发作次数越多相关。
  • FeNO水平升高与肺功能下降相关。
  • FeNO检测具有成本效益,与标准评估方法联合可改善患者管理。
  • 近期证据提示FeNO可能作为重症哮喘评估和管理及预测某些生物治疗反应的替代生物标志物。

关键数值与推荐

  • 英国NICE指南推荐FeNO用于疑似哮喘患者的初始诊断。
  • 美国ATS指南推荐FeNO用于哮喘初始诊断和气道炎症监测。

临床怎么用

  • 在哮喘管理中可用FeNO预测ICS反应、监测依从性及辅助诊断。
  • 对重症哮喘患者,可考虑将FeNO作为评估和预测生物治疗反应的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asthma is a chronic inflammatory disease of the airways, affecting over 350 million people worldwide and placing a significant burden on healthcare providers and wider society. Approximately 5-10% of asthma patients are diagnosed with severe asthma and typically are associated with increased risk of hospitalisation from exacerbations, increased morbidity, mortality and higher asthma-associated healthcare costs. Nitric oxide (NO) is an important regulator of immune responses and is a product of inflammation in the airways that is over-produced in asthma. Fractional exhaled NO (F eNO) is predominantly used as a predictor of response to inhaled corticosteroids (ICSs), to monitor adherence and as a diagnostic tool in ICS-naïve patients. In the UK, the National Institute for Health and Care Excellence (NICE) guidelines recommend the use of F eNO for the initial diagnosis of patients with suspected asthma. In the USA, American Thoracic Society (ATS) guidelines recommend F eNO as part of the initial diagnosis of asthma and for monitoring of airway inflammation. F eNO has also been shown to be a predictive factor for asthma exacerbations, with higher levels being associated with a greater number of exacerbations. In addition, higher levels of F eNO have been shown to be associated with a decline in lung function. F eNO testing is a cost-effective procedure and has been shown to improve patient management when combined with standard assessment methods. Recent evidence suggests that F eNO may also be useful as a surrogate biomarker for the assessment and management of severe asthma and to predict responsiveness to some biological therapies.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Menzies-Gow A, Mansur AH, Brightling CE, et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020. PMID: 31949116. doi:10.1183/13993003.01633-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。